Expertise in
4
conditions

Jane C. Davies

Heath Park, 
Cardiff, WLS, GB 
Expertise in
4
conditions
Heath Park, 
Cardiff, WLS, GB 
OverviewLocationsClinical Research

Overview

Jane Davies practices in Cardiff, United Kingdom. Ms. Davies is highly rated in 4 conditions, according to our data. Her top areas of expertise are Cystic Fibrosis, Pseudomonas Stutzeri Infections, Exocrine Pancreatic Insufficiency, and Bronchiectasis.

Her clinical research consists of co-authoring 250 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Heath Park, Cardiff, WLS, United Kingdom
Other Locations
Manresa Road, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2024
Intervention Type: Drug
Study Drug: Kaftrio
Study Phase: Phase 4
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

249 Total Publications

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.
Journal: American journal of respiratory and critical care medicine
Published: June 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Davies's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile